



# EYEPOINT

PHARMACEUTICALS

26 April 2018

Ms Madeleine Green  
Adviser, Listings Compliance (Perth)  
Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Terrace  
PERTH WA 6000

By email: [Madeleine.Green@asx.com.au](mailto:Madeleine.Green@asx.com.au)

Dear Madeleine

**EyePoint Pharmaceuticals, Inc (formerly pSivida Corp) (ASX:PVA) (the "Company") – Response to price query**

We refer to your letter of 26 April 2018 regarding the change in price of the Company's securities, a copy of which is enclosed with this letter. The Company's responses to the queries in your letter are set out below (adopting the same numbering).

- A. The Company is not aware of any information concerning it which has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.
- B. Not applicable.
- C. On 29 March 2018, the Company announced the acquisition of Icon Bioscience, Inc., together with an equity investment from Essex Woodlands for up to approximately US\$60.5 million and debt financing from SWK Holdings for up to US\$20 million. The material details of those transactions were disclosed to the market in the announcement made by the Company on that date. The Company is not aware of any other information which may explain the recent trading in its securities.
- D. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.



# EYEPOINT

PHARMACEUTICALS

- E. I confirm that the responses set out above have been authorised and approved in accordance with the Company's continuous disclosure policy and that I have the authority of the board to respond to ASX on matters relating to continuous disclosure.

Yours sincerely,

Nancy Lurker  
President and Chief Executive Officer  
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.)

26 April 2018

Lori Freedman  
Company Secretary  
EyePoint Pharmaceuticals, Inc (formally pSivida Corp)  
400 Pleasant Street  
WATERTOWN MA 02472

By email: lfreedman@psivida.com

Dear Ms Freedman

**EyePoint Pharmaceuticals, Inc (formally pSivida Corp) (the “Entity”): price query**

We note the change in the price of PVA’s securities from a low of \$2.16 at the close of trade on Tuesday, 24 April 2018 to a high of \$3.00 today, Thursday 26 April 2018.

We also note the significant increase in the volume of PVA’s securities traded today, Thursday 26 April 2018.

We attempted to contact the Entity between 8:30 am – 8:40 am (AWST) this morning, Thursday 26 April 2018 but was unable to reach to anyone. As such the Entity’s securities have been suspended from trading pending a response to this price and volume query.

ASX asks PVA to respond separately to each of the following questions and requests for information:

- A. Is PVA aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
- B. If the answer to question 1 is “yes”:
  - a) Is PVA relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in PVA’s securities would suggest to ASX that such information may have ceased to be confidential and therefore PVA may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.
  - b) Can an announcement be made immediately?

Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).
  - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
- C. If the answer to question 1 is “no”, is there any other explanation that PVA may have for the recent trading in its securities?
- D. Please confirm that PVA is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
- E. Please confirm that PVA’s responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of PVA with delegated authority from the board to respond to ASX on disclosure matters.

**When and where to send your response**

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible. The Entity’s securities will remain suspending pending a satisfactory response to this price and volume query.

---

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, PVA's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail at [tradinghaltsperry@asx.com.au](mailto:tradinghaltsperry@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

**Listing Rules 3.1 and 3.1A**

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

In responding to this letter, you should have regard to PVA's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

It should be noted that PVA's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

If you have any queries or concerns about any of the above, please contact me immediately.

Kind regards

*[Sent electronically without signature]*

---

**Madeleine Green**

Adviser, Listings Compliance (Perth)